Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multicentric, Randomized, Double Blind, Parallel, Saline Controlled Phase II Clinical Study to Compare the Safety and Efficacy of PMZ-1620 Therapy along with Standard Supportive Care in Subjects of Acute Ischemic Stroke

Next Previous
X
Search
Trial Profile

A Prospective, Multicentric, Randomized, Double Blind, Parallel, Saline Controlled Phase II Clinical Study to Compare the Safety and Efficacy of PMZ-1620 Therapy along with Standard Supportive Care in Subjects of Acute Ischemic Stroke

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sovateltide (Primary)
  • Indications Stroke
  • Focus Adverse reactions
  • Sponsors Pharmazz

    • Most Recent Events

    • 11 Sep 2024 According to a Pharmazz media release, results from this trial will be presented at the 16th World Stroke Congress, taking place from 23-26 October 2024, onsite at the ADNEC, Abu Dhabi.
    • 11 Jan 2021 Results assessing the safety, tolerability and efficacy of sovateltide as an addition to standard of care in patients with acute cerebral ischemic stroke, published in the CNS Drugs
    • 27 Apr 2020 Interim 30-day analysis published in the Pharmazz Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top